کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2956202 1578027 2016 10 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Sustained high blood pressure reduction with etamicastat, a peripheral selective dopamine β-hydroxylase inhibitor
ترجمه فارسی عنوان
کاهش فشار خون بالا و پایدار با etamicastat، دوپامین مهارکننده انتخابی β-هیدروکسیلاز محیطی
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری علم عصب شناسی سیستم های درون ریز و اتونومیک
چکیده انگلیسی


• Dopamine ß-hydroxylase inhibition with etamicastat decreases blood pressure.
• Reduction of blood pressure by etamicastat is sustained during chronic treatment.
• Etamicastat does not prevent the development of hypertension in the SHR.

The aim of the present study was to evaluate the influence of chronic inhibition of dopamine ß-hydroxylase by etamicastat on the development of hypertension in the spontaneously hypertensive rat (SHR) and the sustainability of effects on the systolic and diastolic blood pressure in the SHR and the normotensive Wistar–Kyoto rat (WKY). WKY and SHR received etamicastat (10 mg/kg/d) from 5 weeks of age for 35 weeks in drinking water, and cardiovascular assessments were performed on a weekly basis. Etamicastat reduced systolic and diastolic blood pressure when SHRs reached the age of 16 weeks with mean decreases of 37 and 32 mm Hg, respectively, for the subsequent for 24 weeks of treatment, but did not prevent the increase in blood pressure (BP) aged between 5 and 11 week. The BP lowering effect of etamicastat in SHR was reversible on discontinuation and quickly resumed after reinstatement of therapy and was not accompanied by changes in heart rate. Etamicastat affected neither BP nor heart rate in WKY during 36 weeks of treatment. Etamicastat reduced urinary excretion of norepinephrine to a similar extent in WKY and SHR, accompanied by significant increases in urinary dopamine in SHR. Chronic administration of etamicastat did not adversely affected development of animals. Chronic dopamine ß-hydroxylase inhibition with etamicastat effectively decreases BP, although does not prevent the development of hypertension in the SHR.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Journal of the American Society of Hypertension - Volume 10, Issue 3, March 2016, Pages 207–216
نویسندگان
, , ,